Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $31.52 as of March 10th. TEVA’s trailing and forward P/E were 26.03 and 11.60 respectively according to Yahoo Finance.
Teva Pharmaceutical Industries (TEVA) has entered a new phase of growth as the company continues executing its “Pivot to Growth” strategy, transforming from a traditional generics manufacturer into a higher-margin innovative biopharmaceutical company. Following its Q4 and full-year 2025 results, Teva reported revenues of $17.3 billion, representing 5% year-over-year growth and marking the third consecutive year of revenue expansion.
The company’s growth profile is increasingly driven by its innovative portfolio, highlighted by its three core branded medicines—Austedo, Ajovy, and Uzedy—which together surpassed $1 billion in combined quarterly revenue for the first time in the company’s history. Austedo remains the primary growth engine, generating $2.26 billion in 2025 sales (+34%), supported by strong adoption of its once-daily XR formulation.
Ajovy delivered $673 million in global revenue (+30%), while Uzedy, a rapidly expanding long-acting injectable therapy, grew 63% to $191 million. These innovative medicines now play a central role in Teva’s strategy as the company continues to stabilize its global generics franchise, which generated approximately $9.4 billion in revenue.
Financially, Teva delivered strong results across key metrics in 2025, including adjusted EBITDA of $5.3 billion (+12%), non-GAAP EPS of $2.93 (+19%), and free cash flow of $2.4 billion. The company also made meaningful progress on balance sheet improvement, reducing net debt to $13.3 billion and lowering its net debt-to-EBITDA ratio to 2.5x as it targets 2.0x by 2027. Operational improvements are supported by the Teva Transformation program, which aims to generate $700 million in cost savings by 2027, with roughly 20% already achieved.
Looking ahead, Teva expects 2026 to be a transition year as it absorbs a $1.1 billion headwind from generic Revlimid erosion, guiding revenues to $16.4–$16.8 billion while maintaining strong profitability and free cash flow.
Despite this near-term pressure, the company’s late-stage pipeline—estimated at more than $10 billion in peak sales potential—along with continued expansion of its innovative portfolio positions Teva for sustained mid-single-digit growth through the end of the decade. As leverage declines and free cash flow strengthens, investors increasingly view Teva as a biopharma turnaround with meaningful upside potential as the market begins to recognize the value of its evolving business mix.
